Celcuity

69 articles about Celcuity

• Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences - May 24, 2023

  5/24/2023

  Celcuity Inc. today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences.

• Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

  5/15/2023

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today reported financial results for the first quarter ended March 31, 2023 and provided other recent corporate updates.

• Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

  5/12/2023

  Celcuity Inc. announced that updated results from a Phase 1b trial evaluating gedatolisib, a pan-PI3K/mTOR inhibitor, in combination with palbociclib, a CDK4/6 inhibitor, and letrozole, an aromatase inhibitor, were presented at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress in Berlin, Germany.

• Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

  5/8/2023

  Celcuity Inc., a clinical-stage biotechnology company focused on development of targeted therapies for oncology, announced that it will release its financial results for the first quarter 2023 after the stock market close on Monday, May 15, 2023.

• Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

  5/8/2023

  Celcuity Inc. today announced publication of an abstract reporting updated results for treatment-naive patients from the Phase 1b study of gedatolisib, a pan-PI3K/mTOR inhibitor, in combination with palbociclib and letrozole in women with HR+/HER2- advanced breast cancer (ABC).

• Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

  4/18/2023

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in endometrial, ovarian, and cervical cancer cell lines.

• Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

  4/12/2023

  Celcuity Inc. today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference.

• Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/23/2023

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2022 and other recent business developments.

• Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

  3/16/2023

  Celcuity Inc. today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market close on Thursday, March 23, 2023.

• Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

  3/15/2023

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines.

• Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

  3/1/2023

  Celcuity Inc today announced its participation in Cowen's 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023.

• Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

  2/16/2023

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in prostate cancer cell lines.

• Celcuity Closes $100 Million Private Placement

  12/12/2022

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses.

• Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

  12/9/2022

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that updated results from a Phase 1b trial evaluating gedatolisib were presented during a Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium (SABCS).

• Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

  12/7/2022

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib plus fulvestrant with and without palbociclib for the treatment of patients with HR+/HER2- advanced breast cancer.

• Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

  9/14/2022

  Celcuity Inc. today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors.

• Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/11/2022

  Celcuity Inc., a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, announced financial results for the second quarter ended June 30, 2022 and other recent business developments.

• Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

  8/4/2022

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that it will release its financial results for the second quarter 2022 after the stock market close on Thursday, August 11, 2022.

• Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

  8/3/2022

  Celcuity Inc., a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, announced its participation in the Canaccord Genuity 42nd Annual Growth Conference to be held in Boston on August 8-11, 2022.

• 

  FDA Weekly Review: Avadel, Eton, Pfizer, Celcuity and Others

  7/22/2022

  FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.